Just a few days before Humira knockoffs are set to debut in parts of Europe, AbbVie has settled another round of IP litigation for its ironclad mega-blockbuster franchise in the US.
This time the deal is with Sandoz, Novartis’ generic arm, which has agreed to launch its biosimilar in the US later in 2023 than other competitors will have, per their previous agreements with AbbVie.
Here’s what the succession of launches will look like:
- Amgen: January 31, 2023
- Samsung Bioepis and Merck: June 30, 2023
- Mylan: July 31, 2023
- Sandoz: September 30, 2023
With most countries in the EU, though, Sandoz’s knockoff gets to enter the market on the same day as the others: October 16 of this year.
The stakes are high for AbbVie, which has reaped $18 billion from the world’s biggest blockbuster last year and expects sales to climb $3 billion more in 2020 — driven by annual price hikes. The company can now be fairly certain it has five years to get new drugs lined up to replace the big revenue booster.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription